

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6395424

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
VIZBII TECHNOLOGIES, INC.	10/15/2020
RECEIVING PARTY DATA	
Name:	ADOH SCIENTIFIC, LLC
Street Address:	1321 OVERCREEK COURT
City:	MOUNT PLEASANT
State/Country:	SOUTH CAROLINA
Postal Code:	29464
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9959011
CORRESPONDENCE DATA	
Fax Number:	(864)233-7342
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	864-271-1592
Email:	usdocketing@dority-manning.com
Correspondent Name:	DORITY & MANNING, P.A.
Address Line 1:	P. O. BOX 1449
Address Line 4:	GREENVILLE, SOUTH CAROLINA 29602-1449
ATTORNEY DOCKET NUMBER:	FASX-1-M
NAME OF SUBMITTER:	RICHARD M. MOOSE
SIGNATURE:	/Richard M. Moose Reg. No. 31226/
DATE SIGNED:	11/11/2020
Total Attachments: 2	
source=Oct. 15 2020 Annex A for recordation#page1.tif	
source=Oct. 15 2020 Annex A for recordation#page2.tif	

NUNC PRO TUNC LICENSING AGREEMENT BETWEEN VIZBII TECHNOLOGIES, LLC AND ADOH SCIENTIFIC, LLC, as successor-in-interest to 2KNOWHEALTH, LLC AND TO 1066 AD LLC

THIS AGREEMENT ("Agreement") is hereby made *nunc pro tunc* effective as of May 14, 2020 (the "Effective Date"), between VIZBII TECHNOLOGIES, INC. of Charleston, SC 29403 (hereinafter also "VIZBII") and ADOH SCIENTIFIC, LLC ("hereinafter ADOH"), as successor-in-interest to 2KNOWHEALTH, LLC and to 1066 AD LLC (hereinafter also "1066"), all of Mt. Pleasant, SC 29464.

WHEREAS, VIZBII is the owner of all right, title, and interests to United States Patent No. 9,959,011 and United States Trademark Registration Nos. 5435837 for "MORPHII" and 5226110 for "VIZBII";

WHEREAS, ADOH, as successor-in-interest to 2KNOWHEALTH, LLC and to 1066, has an interest in obtaining various licensing rights to United States Patent No. 9,959,011 and Registration Nos. 5435837 for "MORPHII" and 5226110 for "VIZBII";

WHEREAS, VIZBII and 1066 have concluded a controlling main Agreement between them by which 1066 provides compensation to VIZBII for licensing rights, and by which VIZBII provides such licensing rights, all pursuant to various terms and conditions of such controlling main Agreement, and which has been amended by a First Amendment to fully and totally substitute ADOH for 1066 in such main Agreement, with all rights and duties thereof expressly assumed by ADOH;

VIZBII hereby grants to ADOH *nunc pro tunc* effective as of May 14, 2020 a worldwide, exclusive, sub-licensable, license to manufacture, make, have made, use, sell, have sold, offer for sale, market, promote, import, export, display, distribute, perform or otherwise commercialize or dispose of subject matter covered by United States Patent No. 9,959,011 for health-related outcomes in the healthcare market, from either well-care or sick-care healthcare services, and VIZBII further grants to ADOH *nunc pro tunc* effective as of May 14, 2020 the right to initiate action, suit, or otherwise proceed against and seek recovery from any third party who is infringing United States Patent No. 9,959,011 for health-related outcomes in the healthcare market, from either well-care or sick-care healthcare services (with VIZBII joining and/or joined, if needed), including the right for ADOH to retain any recovery therefrom for the exclusive benefit of ADOH. By way of clarification, exclusivity does not cover customer, employee, and educational experience applications in the healthcare and non-healthcare markets, and all other fields which are not defined as health-related outcomes in the healthcare market, from either well-care or sick-care healthcare services


VIZBII hereby further grants to ADOH *nunc pro tunc* effective as of May 14, 2020 a worldwide, non-exclusive, license to manufacture, make, have made, use, sell, have sold, offer for sale, market, promote, import, export, display, distribute, perform or otherwise commercialize or dispose of subject matter covered by United States Patent No. 9,959,011 and Registration Nos. 5435837 for "MORPHII" and 5226110 for "VIZBII" in the healthcare market generally.


ADoH recognizes that for any trademark and/or service mark rights licensed to ADoH per this Agreement, that VIZBII has the right to review and approve all licensed use of a mark by ADoH or its licensees and to inspect associated goods and/or services provided by ADoH or its licensees under such mark, to ensure quality and consistency of the mark and the associated goods and/or services. VIZBII agrees that such review and/or inspection will not be unreasonably delayed, and that such approval will not be unreasonably withheld or delayed.

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement by their respective authorized representative on the date(s) specified below.

VIZBII TECHNOLOGIES, INC.

ADoH SCIENTIFIC, LLC

DocuSigned by:

E40550FD6D374A9...

DocuSigned by:

FE91F06F6C5D462...

Name: Julie Moreland
Title: CEO

Name: Alfred Fasola
Title: Authorized Member

Date: 10/15/2020
.....

Date: 10/15/2020
.....